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Abstract
Background: Duration of efficacy and safety of lisdexamfetamine dimesylate (LDX) was assessed in adults (18-55 years) 
with attention-deficit/hyperactivity disorder (ADHD) using the simulated adult workplace environment.
Methods: After open-label dose optimization (4-week) with LDX, 30-70 mg/d, subjects entered a 2-week randomized, 
double-blind, placebo-controlled crossover phase. Efficacy assessments included the Permanent Product Measure of 
Performance (PERMP) total score (attempted+correct) measured predose and from 2 to 14 hours postdose, averaged 
across postdose sessions (primary) and at each time point vs placebo (secondary), and ADHD Rating Scale IV (ADHD-
RS-IV) with adult prompts at baseline and crossover visits. Safety assessments included treatment-emergent adverse 
events (TEAEs), vital signs, and electrocardiograms.
Results: Of 127 randomized subjects, 105 were in the intention-to-treat population and 103 completed the study. While 
receiving LDX vs placebo, adults had greater improvement (P < .0001) in average PERMP total scores as measured by 
difference in least squares (LS) mean (95% CI): 23.4 (15.6, 31.2). Absolute (P ≤ .0017 for each time point) and change from 
predose (P < .001 for each time point) PERMP total scores were greater at all postdose time points from 2 to 14 h for adults 
while receiving LDX vs placebo. LDX demonstrated efficacy vs placebo (P < .0001) by the difference in LS mean (95% CI) for 
ADHD-RS-IV total scores: -11.5 (-14.2, -8.9). TEAEs (≥ 10%) during dose optimization were decreased appetite, dry mouth, 
headache, and insomnia; no TEAEs ≥ 5% were reported during crossover phase for adults receiving LDX.
Conclusions: LDX significantly improved PERMP scores vs placebo and maintained improvement throughout the day 
from the first (2 hours) to last (14 hours) postdose time point vs placebo in adults with ADHD.
Trial Registration: ClinicalTrials.gov Identifier: NCT00697515
Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-
Deficit Hyperactivity Disorder (ADHD) http://www.clinicaltrials.gov/ct2/show/NCT00697515?term=NCT00697515&rank=1
Background
Attention-deficit/hyperactivity disorder (ADHD) in
adults has an estimated prevalence of 4.4% in the United
States and 3.4% worldwide [1,2]. Adults with ADHD
experience significant impairment [1,3] in multiple
domains of daily living, including the workplace, home,
and various social settings [3,4].
For many years, pharmacotherapy has been recognized
as having an important role in reducing the core symp-
toms of ADHD in adults [5]. Long-acting oral stimulants
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[6-8] have demonstrated efficacy in managing ADHD
symptoms in adults [7,9-12]. However, in a survey study
completed over a 12-month period in 2004, the
prevalence of treatment for ADHD in adults was only
10.9% [1].
Lisdexamfetamine dimesylate (LDX) is a long-acting
prodrug stimulant indicated for the treatment of ADHD
in children 6 to 12 years of age and in adults in the United
States. LDX is a therapeutically inactive molecule. Fol-
lowing oral ingestion, LDX is converted to l-lysine and
active d-amphetamine. While a small amount of LDX is
hydrolyzed to d-amphetamine in the gastrointestinal
tract, the conversion of LDX into active d-amphetamine
occurs primarily in the blood. The combination of l-lysine
and d-amphetamine created a new chemical entity (a
prodrug) with sustained delivery of d-amphetamine
[13,14]. LDX demonstrated efficacy compared with pla-
cebo by the Permanent Product Measure of Performance
(PERMP) and other assessments in the laboratory school
setting at 12 and 13 hours postdose in children with
ADHD [15,16]. In another pediatric study, LDX was
effective throughout the day, as measured by parent rat-
ings [17]. In these studies, LDX demonstrated a safety
profile consistent with long-acting stimulant use [15-17].
LDX was also effective, with typically mild to moderate
adverse events (AEs), in a large placebo-controlled trial in
adults with ADHD [18]. Common AEs with LDX in this
study included decreased appetite, dry mouth, and
insomnia [18]. Efficacy was assessed through weekly eval-
uations of the ADHD Rating Scale IV (ADHD-RS-IV)
with adult prompts and the Clinical Global Impressions
(CGI) scale. Ratings of efficacy during the course of the
day were not assessed in the initial study [18].
While the factors that determine treatment and choice
of pharmacotherapy are complex, there may be a clinical
need for long-acting stimulant medication with efficacy
beyond 12-hours duration among adults with ADHD
who require symptom control that extends throughout
the day and into evening home and family time [19,20].
To assess and document the duration of efficacy of LDX
throughout the day in adults with ADHD, the present
study compared LDX with placebo in the simulated adult
workplace environment (AWE) setting. Assessments,
including AEs, vital signs, electrocardiogram (ECG), and
physical examination, evaluated the safety profiles of the
2 treatment arms.
The simulated AWE is a structured, controlled environ-
ment based on the model of the laboratory school proto-
col (LSP) [21], designed to monitor and quantitatively
assess response to medication in the performance of
adults during activities simulating those that occur dur-
ing a typical work day [21]. The use of the LSP, and specif-
ically the PERMP assessment, has been applied widely to
evaluate the effects of long-acting stimulants for children
with ADHD [15,22-26]. Although not included in this
study analysis, the LSP may include additional behavioral
assessments such as a revised form of the Swanson, Kot-
kin, Agler, M-Flynn, and Pelham (SKAMP) rating scale
and/or subject-reported behavioral assessment [4] to
evaluate onset and duration of medication effects with
validated, quantitative, and reproducible measures [21].
The simulated AWE is a useful tool for measuring
attention and behavior because structured activities,
designed to provoke behaviors associated with ADHD
symptoms, are provided throughout the day and yield
quantifiable outcomes. PERMP [21], a skill-matched test
consisting of simple math problems to be attempted and
completed at multiple time points throughout the simu-
lated AWE session, is used to measure the ability to stay
on task and attend to work. This instrument measures
how effectively a subject initiates, self-monitors, and
completes written seatwork [21]. It is not a test of the
ability to learn math since the difficulty of problems is
adjusted to the existing math skill level of each subject at
baseline to ensure that each individual achieves ≥ 95%
correct solutions. The PERMP is a validated, time sensi-
tive, skill adjusted math test that measures attention in
ADHD.
The goal of this study was to evaluate the efficacy of
LDX compared with placebo in adults with ADHD in the
simulated AWE setting, and to assess the duration of
effect in a highly structured, controlled environment
from 2 to 14 hours postdose.
Methods
Subjects
Adults (aged 18 to 55 years) with a primary diagnosis of
ADHD were enrolled, based on criteria outlined in the
Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition, Text Revision (DSM-IV-TR™). ADHD
diagnosis was further validated by a comprehensive psy-
chiatric evaluation that included a semi-structured inter-
view based on the Adult ADHD Clinical Diagnostic Scale,
version 1.2 (ACDS v1.2) [27]. All subjects were also
required to have scores on the ADHD-RS-IV with adult
prompts ≥ 28 at baseline and a level of intellectual func-
tioning equivalent to an intelligence quotient of ≥ 80 on
the Kaufman Brief Intelligence Test [28]. Key exclusion
criteria were the presence of a comorbid psychiatric diag-
nosis with significant symptoms, a history of, or per-
ceived risk for future suicide attempt, a recent history of
substance abuse, or other medical conditions that would
contraindicate treatment with psychostimulants or con-
found efficacy and safety assessments. Exclusion criteria
also included a history of seizures; hypertension, with a
resting systolic blood pressure (SBP) > 139 mm Hg or dia-
stolic blood pressure (DBP) > 89 mm Hg; or a history of
symptomatic cardiovascular disease; a structural cardiacWigal et al. Behavioral and Brain Functions 2010, 6:34
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abnormality; or a positive family history of sudden car-
diac death or ventricular arrhythmia. Other exclusion cri-
t eria included adverse reactions or lack of r esponse t o
previous amphetamine therapy, concomitant medica-
tions affecting the central nervous system or blood pres-
sure (with the exception of ADHD medications that were
washed out), pregnancy or lactation, a body mass index
< 18.5 and ≥ 40, or a clinically significant laboratory or
ECG abnormality. Subjects whose current ADHD medi-
cation provided effective control of symptoms with
acceptable tolerability were also excluded.
Study setting
The simulated AWE is a controlled environment based
on the LSP, but modified for the adult 14-hour day. Sub-
jects arrived at 6 AM and departed at approximately 9:30
PM for both AWE sessions. The 2 AWE sessions, spaced
1 week apart in the double-blind phase, were organized
into 3 sequential classes; each class consisting of a sched-
uled series of activities was designed to provoke all of the
DSM-IV-TR™ symptoms of ADHD and to further provide
objective measures of subject performance. In contrast to
the child analog classroom design, the adult design is less
reliant on behavioral observations and primarily focuses
o n  o b j e c t i v e  m e a s u r e s  ( e g ,  P E R M P  m a t h  t e s t ) .  I n  t h e
adult study, other mandatory activities and assignments
were scheduled throughout the day, designed to provoke
specific ADHD symptoms and were collected but not
recorded as measurable assessments. Each classroom
session included several 5-minute transition periods, a
10-minute PERMP test, and 10-minute academic group
games. Key activities performed throughout the simu-
lated AWE day included the presentation of a brief
instructional video on a topic of general information fol-
lowed by a factual quiz, time estimation tasks, practical
checkbook balancing vignettes, and simple grammar
error search tasks. Results from these activities were not
analyzed as formal outcome assessments, but were
included in the AWE day in order to actively involve sub-
jects with effortful, repetitive, and uninteresting tasks
provided to challenge subjects and thereby provoke the
usual symptoms of ADHD [21].
Study design
This randomized, double-blind, placebo-controlled, 2-way
crossover study with an open-label dose-optimization
phase was conducted in a simulated AWE. It was
designed to assess duration of efficacy, tolerability, and
safety of LDX (Vyvanse®, Shire US Inc.) (30, 50, and 70
mg/d) in adults with ADHD. This study was conducted at
5 centers in the United States.
This study was conducted in accordance with the Dec-
laration of Helsinki and Good Clinical Practice according
to the International Conference on Harmonisation guide-
lines. The study protocol was approved by each center's
institutional review board. After complete explanation of
the study to the subjects, written consent was obtained.
The study comprised 4 phases: screening and washout
(6 weeks); open-label dose optimization (4 weeks); dou-
ble-blind crossover (2 weeks) which included 2 full-day
evaluations in the simulated AWE; and a 7-day safety fol-
low-up (Figure 1).
The primary objective was to evaluate the efficacy of
LDX vs placebo by PERMP scores in adults with ADHD
in the simulated AWE. A key secondary objective was to
assess duration of effect over the day of LDX vs placebo in
the simulated AWE with the PERMP administered at -0.5
hours predose and 2, 4, 8, 10, 12, and 14 hours postdose.
Figure 1 Study design. (AWE = adult workplace environment; LDX = lisdexamfetamine dimesylate).Wigal et al. Behavioral and Brain Functions 2010, 6:34
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Other objectives were to assess the efficacy of LDX for
improvement in ADHD symptoms using the ADHD-RS-
IV with adult prompts and to evaluate the improvement
in ADHD symptom severity employing the CGI-Severity
(CGI-S) scale at baseline and the CGI-Improvement
(CGI-I) scale following LDX administration during the
dose-optimization and double-blind phases.
Screening and washout
Except for stimulant medications and sedating antihista-
mines, which were discontinued 7 days prior to assess-
ment of baseline measures, all prohibited medications
were discontinued 30 days prior to screening. After wash-
out, subjects returned to the clinic (baseline, visit 0) for
reassessment of eligibility and to establish baseline safety
and efficacy measures, including the ADHD-RS-IV with
adult prompts, the CGI-S scale, vital signs, and ECG.
Open-label dose optimization
Following screening and washout, eligible subjects
entered the open-label dose-optimization phase, during
which they began receiving LDX and were evaluated for
efficacy and tolerability at weekly visits. The dosage was
initiated at 30 mg/d of LDX and upwardly titrated to the
next available dose at weekly intervals until the optimal
dose was reached. The optimal dose was defined as the
dose that produced an overall minimum reduction in
ADHD-RS-IV with adult prompts symptom score ≥ 30%,
a CGI-I rating of 1 or 2, with tolerable side effects. Tolera-
bility was determined by the investigator, based on a
review of AEs and clinical judgment. Once reached, the
optimal dose was maintained for the remainder of the
dose-optimization phase and was used for the double-
blind phase.
Overall response was assessed and categorized accord-
ing to 3 possible conditions: intolerable response (pres-
ence of intolerable AEs); ineffective response (response to
LDX of < 30% reduction from baseline in the ADHD-RS-
IV score or a CGI-I rating > 2); and acceptable response
(response with ≥ 30% reduction in the ADHD-RS-IV
score and a CGI-I rating of 1 or 2, very much or much
improved, but with tolerable AEs).
Subjects who experienced an intolerable response were
permitted to be down-titrated only once by 20 mg/d to
the next available lower dose. If dose reduction was toler-
ated and ADHD symptom control was acceptable, that
dose was maintained for the remainder of the study. Sub-
jects with an ineffective response were titrated to the next
higher dose (eg, 50 or 70 mg/d), provided AEs were toler-
able. For subjects with an acceptable response and toler-
ance of all prior doses, a further increase to achieve
additional symptom reduction was permitted (to the
maximum of 70 mg/d) at the clinician's discretion.
The last visit at which dosage adjustments could be
made was visit 3 of the dose-optimization phase. For all
randomized subjects, the dose dispensed at visit 3 was
administered during the active week of the crossover
phase. During week 4, visit 4a was to ensure quality-of-
life assessments were completed, while visit 4b was for
the practice AWE sessions.
Double-blind crossover phase
Subjects then entered a 2-week double-blind crossover
phase and were randomized by a fixed-block randomiza-
tion schedule to receive either their optimized dose of
LDX for 7 days followed by placebo for 7 days or placebo
for 7 days followed by their optimized dose of LDX for 7
days. On the last day of the first and second treatment
sequence (visits 5 and 6), assessments of efficacy and
safety of LDX or placebo were collected in the simulated
AWE. Efficacy assessments collected during visits 5 and 6
were as follows: PERMP at -0.5 hour predose and 2, 4, 8,
10, 12, and 14 hours postdose; ADHD-RS-IV and CGI-I
at specified times during the simulated AWE day, as well
as safety assessments including weight measurements
and a 12-lead ECG. Vital signs (ie, SBP, DBP, and pulse)
were also collected at 1 hour predose and 4.5 and 14
hours postdose (± 45 minutes for each). A pregnancy test
and a physical exam were performed during visit 6.
Follow-up
A follow-up by telephone was conducted 1 week after
each subject's last dose of study drug to obtain informa-
tion about any ongoing or new AEs or serious AEs and
concomitant medications.
Outcome measures
Efficacy measures
The primary efficacy endpoint, designed to evaluate the
efficacy of LDX vs placebo, was the total PERMP scale
scores averaged over all postdose time points assessed in
AWE classroom sessions during visits 5 and 6. A second-
ary outcome measure, designed to evaluate the duration
of effect of LDX vs placebo, was the total PERMP scores
at each of the following time points: 2, 4, 8, 10, 12, and 14
hours postdose.
The PERMP, a 10-minute skill-adjusted math test, was
used to evaluate effortful performance in the simulated
AWE as a measure of treatment efficacy. The appropriate
difficulty level for each subject for the PERMP was deter-
mined at screening based on results of a timed math pre-
test. The total PERMP score was the sum of the number
of math problems attempted (PERMP-A) and the number
of  m a t h pr obl em s  a nswe r ed c orr ect ly  (P ERMP -C)  in a
10-minute session. The PERMP was completed through-
out both AWE assessment days (visits 5 and 6).
The ADHD-RS-IV with adult prompts is a clinician-
rated scale that assesses symptoms of ADHD based on
DSM-IV-TR™ criteria [29]. The ADHD-RS-IV consists of
18 items that are grouped into 2 subscales: hyperactivity/
impulsivity and inattention. Each item is scored on a scale
of 0 (no symptoms) to 3 (severe symptoms), yielding aWigal et al. Behavioral and Brain Functions 2010, 6:34
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total score of 0 to 54 [29]. The ADHD-RS-IV was admin-
istered at baseline, visits 1 to 3 and visit 4b of the dose-
optimization phase, and during the 2 AWE sessions, visits
5 and 6. The clinician-rated scale was administered by
trained raters utilizing adult prompts developed at New
York University and Massachusetts General Hospital
[30,31].
The CGI provides a global evaluation of baseline sever-
ity and assesses improvement over time [32]. At baseline,
the investigator used the CGI-S scale to rate severity of
illness on a scale that ranged from 1 (normal, not at all ill)
to 7 (among the most extremely ill subjects). At each visit
thereafter (visits 1 to 3 and 4b of the dose-optimization
phase and the 2 AWE sessions, visits 5 and 6 during the
double-blind phase), the clinician used the CGI-I to rate
improvement relative to baseline on a scale ranging from
1 (very much improved) to 7 (very much worse) [32].
Safety
Safety assessments included monitoring AEs, concomi-
tant medications, vital signs, 12-lead ECGs, and physical
examination. At each study visit, AEs and concomitant
medications were recorded. Resting SBP and DBP, pulse,
temperature, weight, and respiratory rate were assessed
at all study visits, except visit 4a. During AWE days (visit
5 and 6), SBP, DBP, and pulse were assessed at 3 specified
time points. ECGs were conducted at screening, baseline,
and visits 5 and 6. A physical examination was conducted
at screening, baseline, and the end-of-study visit. The
vital signs and ECG results were summarized according
to the actual dose received. Treatment-emergent AEs
(TEAEs), referring to events with onset after the first date
of treatment, and no later than 3 days following termina-
tion of treatment, were recorded separately for the dose-
optimization and the double-blind crossover phases of
the study. TEAEs that continued uninterrupted from the
dose-optimization to the crossover phase without a
change in severity were counted only in the dose-optimi-
zation phase category. TEAEs with a change in severity
across phases or that resolved and then restarted in the
crossover phase were counted both in the dose-optimiza-
tion and crossover arms. TEAEs for which a missing or
incomplete start date made it impossible to determine in
which phase of the study they started were counted as
starting in the dose-optimization phase. TEAEs were
reported as number and percentage of subjects according
to system-organ class, preferred term, treatment group,
and by last dose received at AE onset. AEs were collected
at all visits by soliciting subject report with nonleading
questions, and were coded using the Medical Dictionary
for Regulatory Activities (MedDRA).
Statistics
Based on estimates from earlier simulated AWE and
pediatric laboratory school studies, the ratio between
LDX/placebo differences and within-subject standard
deviation was anticipated to be ≥ 0.49 at the 14-hour
postdose time point, necessitating 90 subjects to com-
plete the study to achieve 90% power for a 2-tailed test at
the significance level of 0.05. With an anticipated dropout
rate of 15% abstracted from previous studies, 106 subjects
were targeted for enrollment.
The intention-to-treat population, defined as subjects
who were randomized and had ≥ 1 primary efficacy mea-
surement (average postdose PERMP total) collected, was
used for primary efficacy analysis of PERMP scores. A
linear mixed effects analysis of variance model, including
treatment, period, and sequence as fixed effects and sub-
jects as a random effect, was used for the primary efficacy
analysis. All efficacy tests were conducted as 2-sided and
at the significance level of 0.05. Two-sided confidence
intervals were constructed with 95% coverage. No impu-
tation of missing data was performed for the PERMP
assessments. For other secondary efficacy measures,
missing scores were imputed if the number of missing
items was < 20% of the total number of items in the scale
or subscale.
Due to the small and varied number of subjects
enrolled per site and the within-subject design of statisti-
cal analyses in this study, analysis by site was not per-
formed and site was not included as a factor in inferential
analyses.
CGI-I ratings are reported in 2 dichotomized groups:
improved, comprising very much and much improved
(CGI-I ratings of 1 or 2), and not improved, comprising
all other scores (CGI-I ratings of ≥ 3) excluding scores of
0 (not assessed). Prescott's test was used to compare
dichotomized CGI-I outcomes during the crossover
phase.
The safety population included all subjects who entered
the dose-optimization phase and received ≥ 1 dose of
LDX, and the randomized safety population included all
subjects who were randomized and received ≥ 1 dose of
blinded study drug during the double-blind crossover
phase.
Results
Demographics and disposition
The study enrolled 142 subjects from 5 study centers (n =
36, 33, 28, 33, and 12) in the United States and was con-
ducted from July to December 2008. All enrolled subjects
were included in the safety population. The demograph-
ics appeared generally balanced between final dose levels
in the dose-optimization phase (Table 1). The safety pop-
ulation had a mean age of 30.5 years and was predomi-
nantly white (89.4%), and male (62.0%), with a predominant
combined ADHD subtype (69.0%). Of enrolled subjects,
127 were randomized and administered a dose of study
medication in the crossover phase, 103 (72.5%) com-Wigal et al. Behavioral and Brain Functions 2010, 6:34
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Table 1: Demographic and baseline characteristics (safety population) by last dose in the dose-optimization phase
Characteristic, mean (SD) LDX
30 mg/d
(n = 28)
LDX
50 mg/d
(n = 70)
LDX
70 mg/d
(n = 44)
LDX
All Doses
(N = 142)
Age (years) 30.5 (9.54) 29.7 (10.71) 31.8 (11.46) 30.5 (10.70)
Weight (lb) 174.7 (43.64) 176.7 (35.22) 182.4 (36.17) 178.1 (37.14)
Height (in) 65.8 (4.30) 68.3 (3.73) 68.3 (3.77) 67.8 (3.97)
Body mass index (lb/in2) 28.2 (5.45) 26.6 (4.79) 27.4 (5.10) 27.2 (5.02)
Gender, n(%)
Male/female 16 (57.1)/12 (42.9) 45 (64.3)/25 (35.7) 27 (61.4)/17 (38.6) 88 (62.0)/54 (38.0)
Race, n (%)
White 21 (75.0) 65 (92.9) 41 (93.2) 127 (89.4)
Black/African American 4 (14.3) 2 (2.9) 0 6 (4.2)
Native Hawaiian/Pacific Islander 2 (7.1) 0 0 2 (1.4)
Asian 1 (3.6) 2 (2.9) 2 (4.5) 5 (3.5)
American Indian/Alaskan Native 0 0 1 (2.3) 1 (0.7)
Other 0 1 (1.4) 0 1 (0.7)
Ethnicity, n (%)
Hispanic or Latino/
Not Hispanic or Latino
2 (7.1)/26 (92.9) 7 (10.0)/63 (90.0) 4 (9.1)/40 (90.9) 13 (9.2)/129 (90.8)
ADHD subtype, n (%)
Inattentive 8 (28.6) 20 (28.6) 11 (25.0) 39 (27.5)
Hyperactive/impulsive 1 (3.6) 3 (4.3) 1 (2.3) 5 (3.5)
Combined 19 (67.9) 47 (67.1) 32 (72.7) 98 (69.0)
ADHD-RS-IV with adult prompts: 
scores at baseline, mean (SD)
Total 37.8 (6.06) 35.8 (4.85) 38.4 (6.12) 37.0 (5.61)
Inattentive 20.9 (3.15) 19.7 (3.45) 20.8 (3.66) 20.3 (3.49)
Hyperactivity/impulsivity 16.9 (5.52) 16.1 (4.35) 17.6 (4.86) 16.7 (4.77)
ADHD = attention-deficit/hyperactivity disorder; ADHD-RS-IV = ADHD Rating Scale IV; LDX = lisdexamfetamine dimesylate.Wigal et al. Behavioral and Brain Functions 2010, 6:34
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pleted the study, and 39 (27.5%) discontinued prema-
turely (Table 2). No subject discontinued due to lack of
efficacy, whereas 6 subjects attributed withdrawal to
TEAEs. Of the subjects who withdrew during the dose-
optimization phase due to TEAEs, 3 withdrew due to ele-
vated blood pressure, and 1 due to cardiac arrhythmia
(frequent premature ventricular complexes). Two sub-
jects withdrew due to TEAEs during the crossover phase:
1 for gastroenteritis and 1 for viral infection. Additionally,
17 subjects withdrew prematurely from the study during
the crossover phase because their study participation
coincided with the occurrence of a natural disaster (ie,
hurricane) in the vicinity of the participating study site,
leading to site closure (listed as Other in Table 2).
Efficacy
LDX demonstrated efficacy vs placebo on the primary
endpoint, the average total PERMP score from all post-
dose assessments during the AWE sessions. The mean
average postdose PERMP total score was significantly
greater (F = 35.47; df [1, 101]; P < .0001) for adults while
receiving LDX vs placebo (Table 3). PERMP was assessed
in 105 subjects, with 1 subject withdrawing from each of
the 2 treatment sequences after the first crossover assess-
ment period (visit 5). Analysis of absolute values of total
PERMP scores at postdose time points demonstrated sig-
nificant efficacy for adults while receiving LDX vs placebo at
each time point (P ≤ .0017). LS mean (SE) change from
predose of the PERMP total score (n = 104) for adults
Table 2: Subject disposition by treatment sequence
Randomization Sequence
n (%) Discontinued Prior to Randomization
(n = 15)
LDX/Placebo
(n = 63)
Placebo/LDX
(n = 64)
All Subjects
(N = 142)
Safety population 15 (100.0) 63 (100.0) 64 (100.0) 142 (100.0)
Randomized safety population - 63 (100.0) 64 (100.0) 127 (89.4)
Intention-to-treat population - 53 (84.1) 52 (81.3) 105 (73.9)
Per protocol population - 49 (77.8) 49 (76.6) 98 (69.0)
Completed study - 52 (82.5) 51 (79.7) 103 (72.5)
Discontinuations 15 (100.0) 11 (17.5) 13 (20.3) 39 (27.5)
Reasons for discontinuations
Total 15 (100.0) 11 (17.5) 13 (20.3) 39 (27.5)
AE 4 (26.7) 0 2 (3.1) 6 (4.2)
Lack of efficacy 0 0 0 0
Refused further participation 5 (33.3) 3 (4.8) 2 (3.1) 10 (7.0)
Protocol nonadherence/
subject noncompliant
00 0 0
Lost to follow-up 2 (13.3) 0 0 2 (1.4)
Other 4 (26.7) 8 (12.7)a 9 (14.1)a 21 (14.8)
aSeventeen subjects withdrew from the study during the double-blind crossover phase due to a natural disaster-related study site closure (ie, 
hurricane).
AE = adverse event; LDX = lisdexamfetamine dimesylate.Wigal et al. Behavioral and Brain Functions 2010, 6:34
http://www.behavioralandbrainfunctions.com/content/6/1/34
Page 8 of 14
while receiving LDX demonstrated significant (P < .001)
efficacy vs placebo at all time points evaluated from
2 hours to 14 hours postdose (Figure 2). Improvement in
average postdose scores was also significantly greater (P <
.0001) for adults receiving LDX vs placebo for PERMP-A
and PERMP-C scores as measured by the difference in LS
mean (Table 3). Analysis of absolute values of PERMP-A
and PERMP-C scores at postdose time points demon-
strated significant efficacy for adults while receiving LDX
vs placebo at each time point (P ≤ .0031). LDX also dem-
onstrated efficacy vs placebo as measured by change from
predose at each postdose time point from 2 hours to
1 4  h o u r s  w i t h  h i g h e r  L S  m e a n  ( S E )  P E R M P - A  a n d
PERMP-C scores for LDX vs placebo (Figure 3).
During the open-label dose-optimization phase with all
subjects receiving LDX, ADHD-RS-IV total scores
decreased. At baseline, mean (SD) ADHD-RS-IV total
scores were 37.0 (5.61). At visits 1, 2, 3, 4b and at dose-
optimization endpoint, mean (SD) change from baseline
scores were -12.3 (8.32), -16.8 (7.83), -20.6 (7.07), -21.6
(7.40), and -21.4 (7.31), respectively (P  < .0001).
Decreases from baseline to dose-optimization endpoint
were also shown with ADHD-RS-IV inattention and
hyperactivity/impulsivity subscores (P < .0001 for each).
Mean (SD) ADHD-RS-IV inattention subscores were
20.3 (3.49) at baseline, and mean (SD) change from base-
line at dose-optimization endpoint was -11.6 (4.33).
Mean (SD) ADHD-RS-IV hyperactivity/impulsivity sub-
scores were 16.7 (4.77) at baseline, and mean (SD) change
from baseline at dose-optimization endpoint was -9.8
(4.38).
The mean (SD) percent change in ADHD-RS-IV total
scores from baseline at visits 5 and 6 (double-blind, cross-
over period) for adults while receiving LDX (all doses)
was -51.5% (24.24) and while receiving placebo was -21.3%
(24.41). The mean ADHD-RS-IV total score was signifi-
cantly lower, indicating better symptom control, for adults
while receiving LDX vs placebo (P < .0001) as measured
by the differences (LDX vs placebo) in LS mean ADHD-
RS-IV total scores during visits 5 and 6 (Figure 4). Signifi-
cant improvements for adults while receiving LDX vs pla-
cebo were also seen for inattention and hyperactivity/
impulsivity subscales as measured by the difference in LS
mean scores (95% CI) during visits 5 and 6: -6.3 (-7.7,
Figure 2 LS Mean (SE) change from predose in PERMP total score from 2 to 14 hours postdose (n = 104/104). (LDX = lisdexamfetamine dime-
sylate; LS = least squares; PERMP = Permanent Product Measure of Performance). LDX-purple diamonds; Placebo-green circles. * P < .001 LDX vs pla-
cebo.Wigal et al. Behavioral and Brain Functions 2010, 6:34
http://www.behavioralandbrainfunctions.com/content/6/1/34
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-4.9; P < .0001) for inattention scores and -5.2 (-6.6, -3.7;
P < .0001) for hyperactivity-impulsivity scores.
At baseline, all subjects (n = 142) were rated moderately
(64.8%), markedly (32.4%), or severely (2.8%) ill by CGI-S
with a mean (SD) score of 4.4 (0.5). During the double-
blind crossover phase, CGI-I ratings suggested that 88
(76.5%) of 115 subjects improved while taking LDX (all
doses) and 27 (23.1%) of 117 subjects improved while tak-
ing placebo. For subjects with valid CGI-I ratings at both
visits 5 and 6, of those randomized to the LDX/placebo
sequence in the crossover phase, 27 of 52 subjects dem-
onstrated improvement (much or very much improved
on the CGI-I) only while receiving LDX; 9 improved only
while receiving placebo. For subjects randomized to the
placebo/LDX sequence, 43 of 51 subjects demonstrated
improvement only while receiving LDX and 4 improved
while only on placebo. LDX was associated with signifi-
cantly (P < .0001) lower CGI-I ratings vs placebo in the
crossover phase (Prescott's test).
Safety
No deaths or serious AEs were reported in this study.
Most reported TEAEs were mild and moderate in sever-
ity. During the dose-optimization phase, the most com-
mon TEAEs of decreased appetite, dry mouth, headache,
insomnia, upper respiratory tract infection, irritability,
nausea, anxiety, and feeling jittery were reported by ≥ 5%
of subjects (Table 4).
During the crossover phase, the overall incidence of
TEAEs was greater while subjects received placebo vs
LDX (Table 5). There were no TEAEs that were reported
by ≥ 5% of subjects while receiving LDX. The TEAEs of
fatigue and upper respiratory tract infection were
reported by ≥ 5% of subjects while receiving placebo,
which contributed to the increased incidence of TEAEs
in subjects receiving placebo vs LDX (12.0% vs 0.9%,
respectively, for fatigue and 7.7% vs 1.7%, respectively, for
upper respiratory tract infection).
At baseline, the mean (SD) for SBP, DBP, and pulse were
119.6 (10.28) mm Hg, 73.8 (7.87) mm Hg, and 72.4
(11.23) bpm, respectively. At the endpoint of the dose-
optimization phase, the mean (SD) for SBP, DBP, and
pulse were 119.3 (10.40) mm Hg, 73.6 (7.65) mm Hg, and
75.6 (9.80) bpm, respectively. During the double-blind
crossover phase, the mean at predose and postdose time
Figure 3 LS mean (SE) change from predose in PERMP-A and PERMP-C scores from 2 to 14 hours postdose (n = 104/104). (LDX = lisdexamfe-
tamine dimesylate; LS = least squares; PERMP-A/-C = Permanent Product Measure of Performance-Attempted/-Correct). PERMP-A: LDX-purple dia-
monds; Placebo-green diamonds; PERMP-C: LDX-blue circles; Placebo-orange circles.* P < .001 LDX vs placebo.Wigal et al. Behavioral and Brain Functions 2010, 6:34
http://www.behavioralandbrainfunctions.com/content/6/1/34
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points on visits 5 and 6 of the A WE days ranged from
118.0 to 120.5 mm Hg for SBP, 71.5 to 73.7 mm Hg for
DBP, and 71.4 to 74.8 bpm for pulse in subjects while
receiving placebo; and from 117.2 to 123.4 mm Hg for
SBP, 73.3 to 75.5 mm Hg for DBP, and 77.0 to 81.0 bpm
for pulse in subjects while receiving LDX (all doses). Con-
sistent with prior clinical studies of LDX, ECG interval
data showed no clinically meaningful trends. At baseline,
the mean (SD) QTcF interval was 384.8 (19.68) msec and
during the double-blind crossover phase (visits 5 and 6)
was 388.8 (20.65) msec for subjects while receiving LDX,
and the mean (SD) QTcF interval at visits 5 and 6 was
389.0 (21.52) for subjects while receiving placebo.
The mean (SD) change in weight at dose-optimization
endpoint vs baseline was -4.0 (4.27) lb. During the cross-
over phase, the mean (SD) change in weight vs baseline
for subjects administered placebo was -2.7 (3.98) and for
subjects administered LDX was -4.4 (4.72) lb. The inci-
dence of subjects who experienced a decrease in weight
that was categorized as a TEAE (based on subject's self-
report and clinician's judgment) was 3.5% (5 of 142 sub-
jects) during the dose-optimization phase with none in
the crossover phase.
Discussion
This is the first study of a medication approved for the
treatment of ADHD to examine efficacy and safety in
adults with ADHD in a structured setting (ie, simulated
AWE) where objective measures of efficacy could be
assessed throughout the day and the first to demonstrate
efficacy (vs placebo) of an approved oral stimulant medi-
cation at 14 hours postdose. While similar studies in
adults are limited, efficacy of long-acting stimulants in
the laboratory school setting has been demonstrated for
children with ADHD across the day and at 12
[15,22,25,33,34] and 13 hours postdose [16]. The findings
of the current study align closely with the results seen in
children in a laboratory school setting [16]. In both stud-
ies, LDX demonstrated significant separation from pla-
cebo through the last postdose time points assessed on an
objective measure of task productivity and accuracy
throughout the day.
I n  t h i s  s t u d y ,  L D X  d e m o n s t r a t e d  e f f i c a c y  c o m p a r e d
with placebo as measured by the average postdose
PERMP math test total scores in this controlled trial in
the simulated AWE setting. Moreover, LDX exhibited
efficacy at all time points measured during the AWE ses-
sions: from 2 hours to 14 hours postdose. Since ADHD
symptoms may extend late into the day [20], the availabil-
ity of treatments that provide efficacy throughout the day,
is important.
LDX demonstrated efficacy compared with placebo in
this study in decreasing symptoms of ADHD as measured
by the ADHD-RS-IV with adult prompts. LDX also dem-
Table 3: Predose and average postdose PERMP scores: PERMP total, PERMP-A, and PERMP-C (n = 104)
Predose PERMP Mean
(SD)
Average Postdose 
PERMP Mean
(SD)
Difference in Postdose 
LS Mean
(95% CI)
(LDX/Placebo)
P Value
PERMP total
While receiving LDX 260.1 (86.23) 312.7 (94.42) 23.4 (15.6, 31.2) < .0001
While receiving placebo 261.4 (74.96) 287.6 (81.45)
PERMP-A
While receiving LDX 132.2 (43.28) 158.4 (47.53) 12.0 (8.1, 15.8) < .0001
While receiving placebo 132.6 (37.62) 145.7 (41.06)
PERMP-C
While receiving LDX 127.9 (43.02) 154.3 (46.96) 11.5 (7.6, 15.4) < .0001
While receiving placebo 128.8 (37.39) 141.9 (40.44)
CI = confidence interval; LDX = lisdexamfetamine dimesylate; LS = least squares; PERMP = Permanent Product Measure of Performance; 
PERMP-A = PERMP-Attempted; PERMP-C = PERMP-Correct.Wigal et al. Behavioral and Brain Functions 2010, 6:34
http://www.behavioralandbrainfunctions.com/content/6/1/34
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onstrated efficacy based on improvements in global
assessment of symptom severity as assessed by clinicians
on the CGI-I scale. These findings support and extend
previous findings that LDX reduced the symptoms and
severity of ADHD compared with placebo in adults in a
4-week controlled trial [18] with measures assessed at
weekly intervals (eg, CGI-I ratings and ADHD-RS-IV
with adult prompts scores). In that randomized, forced-
dose escalation, double-blind, placebo-controlled study
for adult subjects with ADHD, LDX significantly reduced
ADHD symptoms at each dose and at each weekly assess-
ment beginning at week 1 and through study endpoint
compared with placebo.
In the current study, LDX demonstrated a safety profile
consistent with long-acting stimulant use. The common
AEs in the current study, including decreased appetite,
dry mouth, headache, and insomnia, are consistently seen
in studies of long-acting stimulant medications adminis-
tered to adults [12,18,35,36]. As demonstrated in these
other studies, most AEs were mild to moderate in sever-
ity. The effects seen in the current study on weight and
cardiovascular parameters were consistent with those
previously reported for stimulants, including LDX, in
adults [7-9,18,37]. As previously seen for LDX in adult
patients with ADHD [18], LDX administration in the cur-
rent study was associated with modest effects on cardio-
vascular parameters of blood pressure and pulse. Four
subjects withdrew during dose optimization due to car-
diovascular-related TEAEs, supporting the importance of
monitoring cardiovascular parameters during treatment
with stimulants. As with all stimulants, careful attention
to cardiovascular history, symptoms, and clinical findings
in adults with ADHD prior to, and during treatment with,
stimulants is advisable.
Strengths of the study included experimental design
features, such as the multicenter, double-blind, placebo-
controlled, crossover design, and use of the simulated
AWE setting and the validated PERMP to provide assess-
ments of medication efficacy and safety compared with
placebo throughout the day. While studies assessing the
effects of treatment on symptom reduction over an
extended time course (eg, weeks to months) is very useful
in determining global efficacy and safety of medications
for ADHD, it is also important to understand the effects
of medications for ADHD in settings over the course of
the day.
Limitations
There are limitations on the interpretation of the results
o f  t h i s  s t u d y .  T h e  d u r a t i o n  o f  t h e  s t u d y  w a s  r e l a t i v e l y
Figure 4 ADHD-RS-IV total scores at baseline and visit 5/6 and difference in LS mean (95% CI) between LDX and placebo during the double-
blind crossover phase. (ADHD-RS-IV = Attention-Deficit/Hyperactivity Disorder Rating Scale IV; CI = confidence interval; LDX = lisdexamfetamine 
dimesylate; LS = least squares). * P < .0001 LDX vs placebo.Wigal et al. Behavioral and Brain Functions 2010, 6:34
http://www.behavioralandbrainfunctions.com/content/6/1/34
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short. As an assessment of attention to task, ability to stay
on task, and to monitor during repetitive task completion
throughout the day, it should be kept in mind that, by its
design, the PERMP math test setting may result in
increased testing-related arousal. However, the simulated
AWE, which includes multiple practice sessions and
repeated testing sessions is designed to dampen such
arousal. Additionally, the simulated AWE is intended to
be analogous to real-world employment settings only in
the sense of requiring adults to engage in activities that
require attention, mental effort, and a quantifiable out-
come (ie, written work). In this way the AWE is a setting
to elicit ADHD symptoms that might manifest in a work-
place where adults with ADHD are occupied with repeti-
tive, effortful tasks. The exclusion of subjects with active
Table 4: TEAEs during the dose-optimization phase for all 
TEAEs with incidence ≥ 5% in either the dose-optimization 
and/or the crossover phases
AE
Preferred Term, % (n)
Dose-Optimization Phase
(Safety Population)
LDX-All Doses
(n = 142)a
Any TEAE 79.6 (113)
Anxiety 5.6 (8)
Decreased appetite 36.6 (52)
Dry mouth 30.3 (43)
Fatigue 4.9 (7)
Feeling jittery 5.6 (8)
Headache 19.7 (28)
Insomnia 18.3 (26)
Irritability 8.5 (12)
Nausea 7.7 (11)
Upper respiratory tract infection 9.9 (14)
TEAEs were assigned to either the open-label dose-optimization 
phase or the double-blind crossover phase of the study and were 
summarized separately. TEAEs that continued uninterrupted from 
the dose-optimization to the crossover phase without a change in 
severity were counted only in the dose-optimization phase 
category. TEAEs with a change in severity across phases or that 
resolved and then restarted in the crossover phase were counted 
both in the dose-optimization and crossover arms. TEAEs for 
which a missing or incomplete start date made it impossible to 
determine in which phase of the study they started were counted 
as starting in the dose-optimization phase.
aPercentages are based on the number of subjects who received 
each dose at any point during the dose-optimization phase.
AE = adverse event; LDX = lisdexamfetamine dimesylate, TEAE = 
treatment-emergent adverse event.
Table 5: TEAEs during the crossover phase for all TEAEs 
with incidence ≥ 5% in either the dose-optimization and/or 
the crossover phases
AE
Preferred Term, % (n)
Crossover Phase
(Randomized Population)
LDX-All Doses
(n = 115)a
Placebo
(n = 117)a
Any TEAE 27.8 (32) 35.9 (42)
Anxiety 1.7 (2) 0
Decreased appetite 3.5 (4) 1.7 (2)
Dry mouth 3.5 (4) 0.9 (1)
Fatigue 0.9 (1) 12.0 (14)
Feeling jittery 0 0
Headache 1.7 (2) 2.6 (3)
Insomnia 2.6 (3) 1.7 (2)
Irritability 0 0.9 (1)
Nausea 1.7 (2) 0
Upper respiratory tract 
infection
1.7 (2) 7.7 (9)
TEAEs were assigned to either the open-label dose-optimization 
phase or the double-blind crossover phase of the study and were 
summarized separately. TEAEs that continued uninterrupted from 
the dose-optimization to the crossover phase without a change in 
severity were counted only in the dose-optimization phase 
category. TEAEs with a change in severity across phases or that 
resolved and then restarted in the crossover phase were counted 
both in the dose-optimization and crossover arms. TEAEs for 
which a missing or incomplete start date made it impossible to 
determine in which phase of the study they started were counted 
as starting in the dose-optimization phase.
aPercentages are based on the number of subjects who received 
each dose at any point during the crossover phase.
AE = adverse event; LDX = lisdexamfetamine dimesylate, TEAE = 
treatment-emergent adverse event.Wigal et al. Behavioral and Brain Functions 2010, 6:34
http://www.behavioralandbrainfunctions.com/content/6/1/34
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cardiovascular conditions, other unstable medical condi-
tions, or comorbid psychiatric disorders may limit the
applicability of results to the clinically encountered popu-
lation. Additionally, the expected dropout rate of 15% was
exceeded because of an unexpected natural disaster (ie,
hurricane) that resulted in the closure of 1 study site.
Conclusions
LDX demonstrated consistent efficacy compared with
placebo in a structured simulated AWE from 2 hours to
14 hours postdose as assessed by PERMP, a measure
aimed at assessing attention, ability to stay on task, and to
monitor tasks throughout the day. LDX was also effica-
cious in providing overall improvement in the majority of
patients and demonstrated a safety profile consistent with
long-acting stimulant use.
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